Analysts expect Unum Therapeutics Inc (NASDAQ:UMRX) to report ($0.31) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Unum Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.41). Unum Therapeutics posted earnings of ($0.29) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 6.9%. The company is scheduled to issue its next quarterly earnings results on Thursday, March 26th.
On average, analysts expect that Unum Therapeutics will report full-year earnings of ($1.42) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.34). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.60) to ($0.73). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.07). Unum Therapeutics had a negative net margin of 388.07% and a negative return on equity of 96.07%. The firm had revenue of $1.02 million during the quarter, compared to analyst estimates of $4.41 million.
Several hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC grew its stake in shares of Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock worth $85,000 after acquiring an additional 18,717 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in Unum Therapeutics during the third quarter worth $31,000. Susquehanna International Group LLP acquired a new position in Unum Therapeutics during the second quarter worth $62,000. Wedbush Securities Inc. bought a new position in Unum Therapeutics in the third quarter valued at $48,000. Finally, Jane Street Group LLC bought a new position in Unum Therapeutics in the second quarter valued at $132,000. 43.02% of the stock is owned by institutional investors.
Unum Therapeutics stock traded down $0.02 during mid-day trading on Friday, hitting $0.67. 206,530 shares of the company’s stock were exchanged, compared to its average volume of 146,254. The company’s 50 day simple moving average is $1.10 and its 200-day simple moving average is $1.96. The company has a quick ratio of 1.96, a current ratio of 1.96 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $22.55 million, a P/E ratio of -0.48 and a beta of 1.01. Unum Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $6.74.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Read More: What Does a Sell-Side Analyst Rating Mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.